About US
Contact us
-
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's diseaseWith another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara. Th2025/3/18
-
Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with PfizerDespite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. And now, the Massachusetts-ba2025/3/18
-
Investor group calls for strategy shift as Amarin shares continue to flounder post-Sarissa Capital takeoverActivist investor Sarissa Capital won control over Amarin’s board two years ago on a fierce campaign of stirring up value for shareholders. But after another year of lacklustersalesand declining shar2025/3/13
-
Calling UK 'uninvestable,' pharma giants demand revamp of drug cost control policyGlobal pharma giants AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Pfizer and more are calling for the U.K. government to afford the industry more room for growth by revising a2025/3/13
-
Amid Trump's push to abolish DEI, Roche and Novartis adjust hiring initiatives: reportsTwo months after U.S. President Donald Trump issued anexecutive orderproclaiming diversity, equity and inclusion (DEI) programs “illegal and immoral,” Roche hasscrappeditshigh-profileplanto increase2025/3/11
-
Purdue Pharma files new $7.4B bankruptcy reorganization plan to settle opioid claimsPreviously at theepicenterof the U.S. opioid crisis, Purdue Pharma is looking to reenter the public lexicon as a new public benefit company. After a prior bankruptcy settlement was nixed by the Supre2025/3/11
-
Novartis details intrathecal Zolgensma data in bid to reach more SMA patients with gene therapyA pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the treatment of older patients with spinal muscular atrophy (SMA). Among SMA p2025/3/6
-
WuXi AppTec offers rosy 2025 guidance despite threat of US-China trade tensionsWith the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. Still, geopolitical uncertainties under the second Trump administration loom large over th2025/3/6
-
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longerAstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partn2025/3/4
-
Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic strokeOver nearly the last three decades, Genentech has had the lone medicine on the market for the acute treatment of stroke. Monday, the Roche subsidiaryaddeda second stroke treatment to its repertoire,2025/2/28